Rewriting the Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner

FEB 18, 202641 MIN
IDEA Collider: Innovation & Asymmetric Learning in Pharma

Rewriting the Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner

FEB 18, 202641 MIN

Description

In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases. Michelle shares how engineered transfer RNA (tRNA) technology has the potential to address nonsense mutations — a single class of genetic errors that account for roughly 10% of genetic diseases, affecting millions worldwide. Rather than the traditional “one drug, one disease” model, Alltrna is pursuing a mutation-targeted strategy that could treat multiple diseases with a single therapeutic platform. Episode Timestamps;00:00 Welcome to Idea Collider: Asymmetric Learning in Pharma00:19 Meet Michelle Werner: Leading Alltrna’s tRNA Platform02:09 From Cancer Clinic to Pharma: A Patient-First Career Path06:18 Big Pharma vs Biotech CEO: Finding Your Authentic Leadership Style09:37 Vulnerability & Psychological Safety: Building High-Trust Teams11:46 A Personal Turning Point: Her Son’s Duchenne Diagnosis17:11 Rare Disease Renegades: A Nonprofit to Accelerate Innovation18:19 Why Flagship Pioneering: The Ecosystem Behind Alltrna22:31 tRNA 101: Targeting Stop-Codon Disease Across Thousands of Conditions28:46 Rethinking Trials, Indications & FDA Pathways for Mutation-First Medicines33:49 From Preclinical to First-in-Human: Alltrna’s 2026 Milestones36:49 What Keeps a CEO Up at Night + Final Takeaway: Is This Rare Disease’s Inflection Point? Michelle also reflects on how her personal experience as a parent of a child with a rare condition fuels her commitment to accelerating therapies for patients who currently have few or no options. This episode highlights a pivotal question for the industry:Are rare diseases at the same inflection point oncology experienced two decades ago? Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Michelle Werner;LinkedIn: https://www.linkedin.com/in/michelle-c-werner/Website: https://www.alltrna.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/